Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05618587 · ClinicalTrials.gov registry record · Phase 2
Effect of Lithium Therapy on Long COVID Symptoms
A Phase 2 study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT05618587 is a Phase 2 study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 52 participants.
The verdict
NCT05618587, a Phase 2 study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study will assess low-dose lithium's effects on several different symptoms experienced by long COVID patients.
Interventions
- DRUG Placebo
- DRUG Lithium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-11-28 |
| Est. Completion | 2023-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05618587
The ClinicalTrials.gov registry entry for NCT05618587 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05618587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05618587 about?
NCT05618587 is a clinical study titled "Effect of Lithium Therapy on Long COVID Symptoms". This study will assess low-dose lithium's effects on several different symptoms experienced by long COVID patients.
What is the current status of trial NCT05618587?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2022-11-28. Estimated completion is 2023-07-21.
What interventions are being tested in trial NCT05618587?
The interventions under investigation include: Placebo (DRUG), Lithium (DRUG).
Who is sponsoring clinical trial NCT05618587?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.